Biohaven completes enrollment in Phase 3 study of taldefgrobep alfa

Biohaven announced completing enrollment in RESILIENT, the Phase 3 pivotal study of taldefgrobep alfa in spinal muscular atrophy. Biohaven targeted randomizing approximately 180 patients in this global trial conducted in 9 countries. The primary objective is to determine the safety and efficacy of taldefgrobep alfa compared to placebo after 48 weeks of subcutaneous administration as determined by change from baseline in the 32 item Motor Function Measure total score.